A detailed history of Private Advisor Group, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Private Advisor Group, LLC holds 7,244 shares of VRTX stock, worth $3.64 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
7,244
Previous 8,221 11.88%
Holding current value
$3.64 Million
Previous $3.85 Million 12.56%
% of portfolio
0.02%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$460.0 - $505.78 $449,420 - $494,147
-977 Reduced 11.88%
7,244 $3.37 Million
Q2 2024

Aug 05, 2024

BUY
$392.81 - $485.53 $95,452 - $117,983
243 Added 3.05%
8,221 $3.85 Million
Q1 2024

Apr 30, 2024

SELL
$407.69 - $446.08 $955,217 - $1.05 Million
-2,343 Reduced 22.7%
7,978 $3.33 Million
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $171,500 - $205,340
500 Added 5.09%
10,321 $4.2 Million
Q3 2023

Nov 02, 2023

SELL
$338.18 - $362.46 $978,692 - $1.05 Million
-2,894 Reduced 22.76%
9,821 $3.42 Million
Q2 2023

Aug 09, 2023

BUY
$314.42 - $351.91 $2.07 Million - $2.32 Million
6,591 Added 107.63%
12,715 $4.47 Million
Q1 2023

May 10, 2023

SELL
$283.23 - $323.1 $337,893 - $385,458
-1,193 Reduced 16.3%
6,124 $1.93 Million
Q4 2022

Jan 18, 2023

BUY
$285.76 - $321.48 $433,497 - $487,685
1,517 Added 26.16%
7,317 $0
Q3 2022

Oct 14, 2022

SELL
$273.83 - $305.53 $7.11 Million - $7.93 Million
-25,971 Reduced 81.74%
5,800 $1.68 Million
Q2 2022

Jul 13, 2022

BUY
$234.96 - $292.55 $506,338 - $630,445
2,155 Added 7.28%
31,771 $8.95 Million
Q1 2022

May 12, 2022

SELL
$221.42 - $260.97 $301,795 - $355,702
-1,363 Reduced 4.4%
29,616 $7.73 Million
Q4 2021

Feb 10, 2022

SELL
$177.01 - $223.45 $159,840 - $201,775
-903 Reduced 2.83%
30,979 $6.8 Million
Q3 2021

Oct 14, 2021

BUY
$181.39 - $202.99 $717,397 - $802,825
3,955 Added 14.16%
31,882 $5.78 Million
Q2 2021

Aug 12, 2021

BUY
$187.49 - $221.1 $3.07 Million - $3.62 Million
16,382 Added 141.9%
27,927 $5.63 Million
Q1 2021

Apr 22, 2021

BUY
$207.02 - $241.31 $287,550 - $335,179
1,389 Added 13.68%
11,545 $2.48 Million
Q4 2020

Apr 01, 2021

BUY
$207.01 - $276.09 $240,545 - $320,816
1,162 Added 12.92%
10,156 $2.4 Million
Q3 2020

Nov 02, 2020

BUY
$255.65 - $303.1 $459,914 - $545,276
1,799 Added 25.0%
8,994 $2.51 Million
Q2 2020

Aug 17, 2020

BUY
$225.48 - $295.8 $505,977 - $663,775
2,244 Added 45.32%
7,195 $2.09 Million
Q1 2020

May 12, 2020

BUY
$199.77 - $247.81 $52,339 - $64,926
262 Added 5.59%
4,951 $1.18 Million
Q4 2019

Feb 10, 2020

SELL
$166.71 - $223.91 $153,373 - $205,997
-920 Reduced 16.4%
4,689 $1.03 Million
Q3 2019

Nov 13, 2019

BUY
$166.23 - $187.09 $298,881 - $336,387
1,798 Added 47.18%
5,609 $996,000
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $128,066 - $148,107
-778 Reduced 16.95%
3,811 $691,000
Q1 2019

May 13, 2019

BUY
$163.73 - $194.7 $78,754 - $93,650
481 Added 11.71%
4,589 $845,000
Q4 2018

Feb 11, 2019

SELL
$151.91 - $192.21 $160,113 - $202,589
-1,054 Reduced 20.42%
4,108 $681,000
Q3 2018

Nov 01, 2018

BUY
$167.73 - $192.74 $281,786 - $323,803
1,680 Added 48.25%
5,162 $995,000
Q2 2018

Aug 09, 2018

BUY
$145.72 - $169.96 $150,965 - $176,078
1,036 Added 42.35%
3,482 $591,000
Q1 2018

May 09, 2018

SELL
$151.6 - $177.13 $233,312 - $272,603
-1,539 Reduced 38.62%
2,446 $399,000
Q4 2017

Feb 07, 2018

SELL
$137.28 - $155.55 $267,421 - $303,011
-1,948 Reduced 32.83%
3,985 $621,000
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $70,509 - $77,226
476 Added 8.72%
5,933 $921,000
Q2 2017

Aug 10, 2017

BUY
N/A
5,457
5,457 $702,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Private Advisor Group, LLC Portfolio

Follow Private Advisor Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Advisor Group, LLC with notifications on news.